Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

1 Oct 2013

Abstract excerpt

PURPOSE: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). METHODS: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ocular Diseases and Behçet’s Syndrome
Share to Ophthalmology and Visual Impairment Studies
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24143065
DOI: 10.2147/opth.s39635

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationPMID 24143065Read ↗

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.Semantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).Semantic proximity Read ↗

Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.Semantic proximity Read ↗

Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.Semantic proximity Read ↗

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Semantic proximity Read ↗

Genetic markers of the effectiveness of anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.